Schießl IM, Castrop H. Angiotensin II AT2 receptor activation attenuates AT1 receptor-induced increases in the glomerular filtration of albumin: a multiphoton microscopy study. Am J Physiol Renal Physiol 305: F1189 -F1200, 2013. First published August 14, 2013; doi:10.1152/ajprenal.00377.2013In this study, we assessed the acute effects of angiotensin II on the albumin glomerular sieving coefficient (GSC) using intravital microscopy. The experiments were performed on Munich Wistar Froemter (MWF) rats. Alexa-Fluor-594 albumin was injected intravenously, and the fluorescence intensity in the glomerular capillaries and Bowman's space was determined to calculate the albumin GSC. The GSC was measured before and during the constant infusion of angiotensin II (10 ng·min Ϫ1 ·kg Ϫ1 body wt). Baseline mean arterial pressure (MAP) was 99 Ϯ 5 mmHg and stabilized at 137 Ϯ 5 mmHg during angiotensin II infusion. The baseline GSC averaged 0.00044 Ϯ 4.8 ϫ 10 Ϫ5 and increased by 286 Ϯ 44% after angiotensin II infusion (P Ͻ 0.0001). The proximal tubular Alexa-Fluor-594 albumin uptake was enhanced during angiotensin II infusion (518% of the baseline value during angiotensin II vs. 218% in controls; P Ͻ 0.0001). No change in GSC was observed when the AT1 antagonist losartan was injected before the start of angiotensin II infusion. The AT2 antagonist PD123319 increased the baseline GSC from 0.00052 Ϯ 3.6 ϫ 10 Ϫ5 to 0.00074 Ϯ 8.2 ϫ 10
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(P ϭ 0.02) without altering the MAP. During angiotensin II infusion with losartan, PD123319 increased the albumin GSC from 0.00037 Ϯ 5.8 ϫ 10 Ϫ5 to 0.00115 Ϯ 0.00015 (P ϭ 0.001). When the renal perfusion pressure was mechanically controlled, the GSC increased from 0.0007 Ϯ 0.00019 to 0.0025 Ϯ 0.00063 during angiotensin II infusion (P ϭ 0.047), similar to what was observed when the renal perfusion pressure was allowed to increase. In summary, AT 1 activation acutely increases the albumin GSC. This effect appears to be largely independent of changes in the renal perfusion pressure. The AT 2 receptor partially attenuates the proteinuric effects of the AT1 receptor.
angiotensin II; AT receptors; glomerular filtration barrier; mulitphoton microscopy; proteinuria INHIBITING THE RENIN-ANGIOTENSIN system (RAS) is a common practice used to manage proteinuria. The antiproteinuric effect of blocking the RAS is generally considered to be primarily related to hemodynamic effects (30) . Therefore, a reduction in renal perfusion pressure and changes in glomerular capillary pressure may influence filtration of macromolecules such as albumin. Furthermore, the direct effects of angiotensin II on the glomerulus may cause pressure-independent changes in protein filtration. For example, mesangial cells in culture have been shown to constrict in response to angiotensin II, which may influence the sieving coefficient (39) . Furthermore, the angiotensin AT 1 receptor is present on podocytes, and angiotensin II causes changes of the cytoskeleton of the podocytes that may affect the structure of their foot processes, which determine the integrity of the filtration barrier (13, 36, 37) . In addition to the AT 1 receptor, podocytes also express the AT 2 receptor; however, the functional relevance of this expression remains largely unknown (36, 38, 44) .
Determining the glomerular sieving coefficient (GSC) of macromolecules such as albumin is difficult because of the limited access to Bowman's space. Therefore, studies on the effects of angiotensin II on the filtration barrier often use artificial macromolecules, such as Ficoll, that can be analyzed by measuring the amount excreted in the urine and are not masked by the effects of upstream tubular uptake. Using the findings obtained from these types of experiments to predict the filtration process of endogenous molecules (especially albumin) is difficult because of the differences in specific charge and conformation between the proteins and Ficoll. In a recent study, it was shown that an increase in the glomerular filtration of a FITC-labeled Ficoll with a molecular mass between 70 and 400 kDa occurs in response to angiotensin II infusion and that this effect is mediated by the AT 1 receptor (3).
In this study, we used multiphoton microscopy in rats to assess the acute (i.e., without preexisting lesions in the filtration barrier) effects of angiotensin II on the filtration of albumin in live animals. Recent studies using multiphoton microscopy have challenged the classic view on the permeability of the glomerular filtration barrier for large molecules by suggesting that proteins are filtered at nephrotic levels under baseline conditions and are subsequently reabsorbed by the proximal tubule (31, 32) . Other studies using essentially the same method, however, have determined that the GSC of albumin is in a substantially lower range that is closer to the range reported in earlier micropuncture studies (21, 26, 41) .
We found that the GSC of albumin in the rat was very low under baseline conditions, which indicates that there is an effective filtration barrier for large proteins. Angiotensin II caused a rapid increase in the GSC of albumin that was largely independent of renal perfusion pressure and was accompanied by an increase in the proximal tubular albumin uptake. The proteinuric effects of angiotensin II were mediated by the AT 1 receptor and were partially counteracted by activation of the AT 2 receptor. These findings suggest that AT 1 receptor antagonists may be more efficient at attenuating angiotensin IIinduced proteinuria than angiotensin-converting-enzyme inhibitors (ACEi).
METHODS

Animals
Animal experiments were performed using Munich Wistar Froemter (MWF) rats from a breeding colony at the University of Regensburg. Young female rats 6 -8 wk of age were used in the experiments (110 to 160 g). The animals were fed a standard diet and kept on a 12:12-h light-dark cycle. All of the animal care procedures and experiments were approved by the Institutional Animal Care and Use Committee of the University of Regensburg and were conducted according to the National Institutes of Health's Guidelines for the Use of Laboratory Animals.
Animal Preparation
For the multiphoton microscopy experiments, rats were anesthetized with 113 mg/kg thiobutabarbital (Inactin) by intraperitoneal injection. The body temperature was maintained at 37.5°C by placing the animals on an operating table with a servo-controlled heating plate. The right carotid artery or the femoral artery was cannulated using hand-drawn polyethylene tubing so that the arterial blood pressure and heart rate could be measured continuously. A cannula connected to an infusion pump was inserted into the right jugular or femoral vein for the intravenous infusion of either saline or an angiotensin II solution and for the injection of drugs and fluorescent dyes. For the imaging session, the left kidney was exposed by making a small flank incision.
Experimental Protocols
Acute effects of angiotensin II on the albumin GSC. The albumin GSC was determined in seven animals before starting the infusion of angiotensin II (Sigma), which was dissolved in saline at a dosage of 10 ng·kg Ϫ1 ·min Ϫ1 ; the constant infusion flow rate was set to 0.09 l·g Ϫ1 ·min Ϫ1 . The albumin GSC measurements were then taken again 10 -15 min after the start of the angiotensin II infusion. To be able to adjust for the time-and volume-dependent changes in the albumin GSC, saline was infused in four control animals instead of the angiotensin II solution at the same infusion rate (0.09 l·g Ϫ1 ·min Ϫ1 ). The albumin GSC measurements were taken within the same time frames used for the infusion of angiotensin II.
Role of the AT1 receptor in the angiotensin II-mediated changes in the albumin GSC. Losartan (9.9 g/g body wt) dissolved in saline was injected intravenously into five animals 25 min after the beginning of the angiotensin II infusion. Changes in the albumin GSC were determined 5 min after the losartan injection. A control experiment was performed by infusing saline (0.09 l·g Ϫ1 ·min Ϫ1 ) instead of the angiotensin II solution in four animals.
In a second experiment, 9.9 g/g of losartan was injected into two animals before the start of the angiotensin II infusion, and the albumin GSC was subsequently determined.
Role of the AT2 receptor in the angiotensin II-mediated changes in the albumin GSC. The albumin GSC was determined in five animals under the baseline condition. Then, PD123319 (3 g/g in saline) was injected immediately before the angiotensin II infusion was started. Changes in the albumin GSC were determined 10 -15 min after the beginning of the angiotensin II infusion. Additionally, 9.9 g/g of losartan were injected 25 min after the start of the angiotensin II infusion, and the albumin GSC was remeasured 5 min later.
A control experiment was performed using four animals to assess the role of the AT2 receptor at the endogenous angiotensin II concentration level. After the baseline albumin GSC was determined, 3 g/g of PD123319 was injected immediately before the saline infusion was started (0.09 l·g Ϫ1 ·min Ϫ1 ). Changes in the albumin GSC were determined 10 to 15 min after the saline infusion was started.
Role of the MAP in the angiotensin II-induced changes in the albumin GSC. A string loop was implanted around the abdominal aorta upstream of the renal artery branching so that the renal perfusion pressure could be mechanically manipulated by pulling on the string loop. The mean arterial pressure (MAP), a correlate of the renal perfusion pressure, was recorded in the femoral artery. The femoral vein was cannulated for dye injection and the infusion of angiotensin II. After the baseline albumin GSC was determined, two different experiments were conducted.
In a first experiment, an angiotensin II infusion was started without manipulating the renal perfusion pressure (3 animals). Approximately 10 -15 min after the infusion was started, the albumin GSC was determined during normal renal perfusion pressure. Next, the GSC was determined after mechanically reducing the renal perfusion pressure back to the baseline level by pulling the string loop.
In the second experiment, the renal perfusion pressure was manipulated in three animals to suppress changes in the arterial pressure in the femoral artery (which should also suppress changes in the pressure of the renal artery) by simultaneously pulling the string loop and starting the angiotensin II infusion. The albumin GSC for each animal was determined 10 -15 min after the start of the angiotensin II infusion, and these values were compared with the baseline values.
Determination of the Angiotensin II-Mediated Changes in the Urine Albumin Content
In five anesthetized animals, the bladder was exposed and punctured using a 30-G, U-40 insulin syringe. The bladder was completely drained of urine before starting the angiotensin II infusion. The MAP was monitored during the angiotensin II infusion, and the bladder was punctured again after 45 min.
Multiphoton Microscopy
The experiments were performed using a Zeiss LSM 710 NLO confocal fluorescence microscope (Carl Zeiss Jena, Jena, Germany) equipped with a servo-controlled warming plate to maintain the body temperature of the animal at 37°C (34) . Excitation was achieved using a Chameleon Ultra-II MP laser (Coherent Deutschland, Dieburg, Germany) at 860 nm with a laser power of 22% of 3,200 mW. Sixteen-bit 512 ϫ 512 pixel images (providing a theoretical dynamic range for intensities measurements of 0 -65,536 pixel intensity) were obtained using a pixel dwell time of 1.27 s and a line average of one by applying a ϫ40 long distance (LD) C-Apochromat 40/1.1 water objective. The emissions were collected using external detectors [nondescanned detectors with filter set 1 (green channel): beamsplitter 500 -550, long pass (LP) 555 and filter set 2 (red channel): beamsplitter P 565-610 including mirror] and internal detectors (blue channel: 420 -440/main beamsplitter: 458). The detector settings were kept constant for all measurements: for the green, red, and blue channels, respectively, the master gain was 500/500/500, the digital gain was 10/10/10, and the offset was Ϫ4,000/Ϫ3,500/Ϫ3,000.
To label the vasculature, a 5 mg/ml solution of Alexa Fluor 594 BSA conjugate (Invitrogen, Darmstadt, Germany) dissolved in PBS was first purified by dialysis for 3 days (Spectra/Por Float-A-Lyzer, 50 kDa; Spectrum Europe B.V., Breda, The Netherlands), then concentrated using Nanosep Centrifugal (VWR International, Darmstadt, Germany) and injected intravenously (1.3 l/g). The fluorescence was detected using the red channel. The proximal tubules were visualized by collecting autofluorescence (green channel), and the collagen was visualized using second harmonic generation (SHG, blue channel). For determination of the single nephron glomerular filtration rate, a bolus injection of Lucifer yellow (LY; Invitrogen; 2.5 mg/ml) was administered intravenously and the fluorescence was detected in the green channel.
Determination of the Albumin GSC
The GSC was defined as the ratio of the albumin concentration in the filtrate (in Bowman's space) to the albumin concentration in the plasma (in the glomerular capillaries). In this study, the albumin GSC was determined using multiphoton microscopy to determine the ratio of the fluorescent intensity of the Alexa Fluor 594 BSA conjugate.
For each animal, two to four superficial glomeruli were selected using visible (green) light from a mercury arc lamp. All of the measurements were taken at a depth of 30 m underneath the kidney capsule (identified by the SHG of the collagen) to keep the intensity values between measurements comparable. For each measurement, six images were collected with a time lapse of 10 s to minimize laser-induced tissue damage. Before the dyes were injected, six background images for each glomerulus were collected using identical recording settings. A z-stack was constructed for each of the selected glomeruli to assess the three-dimensional structure of glomerular capillaries and to ensure that the fluorescent values measured in the Bowman's space were not artificially increased by out-of-focus fluorescence from the capillaries in the immediate vicinity below or above the focal plane. To prevent the tissue from photo-bleaching, the laser power used to generate the z-stacks was reduced to 18%.
To determine the albumin GSC, the fluorescent intensity in three regions of interest (ROIs; 150 pixels each) within the glomerular capillary loops and two ROIs in the Bowman's space were measured for each of the six images (Fig. 1A) . For the fluorescence intensity in the plasma, the ROIs were placed within the outer margins of the capillaries showing the brightest fluorescence in the field. The ROIs in the Bowman's space were selected in regions apart from capillaries. To measure the background fluorescence intensities, four ROIs were selected in Bowman's space and two ROIs were selected within the capillary loops of each analyzed image (Fig. 1B) .
GSC calculations were based on the average intensity values after subtracting the background fluorescence for the plasma and Bowman's space using the following formula: albumin GSC ϭ (intensity Bowman's space Ϫ intensity background Bowman's space)/(intensity capillaries Ϫ intensity background capillaries).
Lower Limit of Detection for the Fluorescent Intensity in Bowman's Space
The lower limit of detection (LLD) for the intensity values in the Bowman's space was calculated for each experiment as previously described (1, 41) . The calculated values for the albumin GSC were only used in further analyses if the mean fluorescence intensity value of the Alexa-BSA in the Bowman's space exceeded the value of the LLD.
Proximal Tubular Albumin Uptake
The proximal tubular albumin uptake was measured as the increase in the tubular fluorescence intensity during the time interval after the start of the Alexa-albumin injection and is given as a percent of the baseline fluorescence intensity. The measurements were taken from seven images of the baseline condition collected immediately after the Alexa-albumin injection and seven images collected 45 min after the start of the saline and angiotensin II infusions. The fluorescent intensity of four areas in the proximal tubules (400 pixels each) was determined per image. The calculations for the proximal tubular albumin uptake were based on the average intensity values after subtracting the background readings for the proximal tubular autofluorescence (which was assessed simultaneously).
Determination of the Single Nephron Glomerular Filtration Rate
The single nephron glomerular filtration rate (snGFR) was quantified in four animals using multiphoton microscopy as snGFR ϭ V[nl]/⌬t[s]. Per animal, four superficial glomeruli were selected, in which the first 60 m of the proximal tubule were positioned within the same optical section. For each measurement, a movie was captured during a bolus injection (5 l) of a 2.5 mg/ml LY solution. The time difference between the fluorescence maximum was measured in ROI 1, positioned at the beginning of the proximal tubule, and ROI 2, positioned 60 m downstream of ROI 1. For the determination of the tubular fluid volume V, a z-stack was acquired using decreased laser A B Fig. 1 . Measurement of the glomerular sieving coefficient (GSC) of albumin in the rat using multiphoton microscopy. A: 3 regions of interest (ROI, ovals) within the outer margin of the glomerular capillary (where the maximum fluorescence intensities were acquired) and 2 ROIs in the Bowman's space were selected for intensity measurements. B: background intensities were determined in 2 ROIs within the capillaries and 4 ROIs in the Bowman's space before injecting the Alexa Fluor 594 BSA conjugate. A grey-scale range indicator was used in the image to visualize the contours of the glomerular capillaries.
power (18%), and the diameter of the first 60-m intercept was measured. The tubular fluid volume was then calculated according to the formula: V ϭ [length ϫ (diameter/2)
2 ϫ ]. The values for the snGFR were calculated as the mean of five measurements. Changes in the snGFR during the infusion of angiotensin II were assessed as paired observations.
Quantification of the Urinary Albumin Excretion
To quantify the urinary albumin content, the urine samples before infusion were diluted 1:6 and the urine samples taken during the angiotensin II infusion were diluted 1:10. The diluted samples were separated on a 10% SDS-PAGE gel. Albumin BSA standard solutions (0.1/0.25/0.5/1.0/2.0/4.0 g/l) were prepared and separated on the gel. A Coomassie staining was performed to visualize the albumin content, and the amount of albumin in the samples was analyzed by densitometry. The urine albumin content was normalized against the urine osmolarities, which were determined using the freezing point depression method (25) .
Quantitative Image Analyses and Statistics
Multiphoton microscopy images were analyzed using the ZEN 2010 64-bit software (Carl Zeiss Jena, Jena, Germany). The Coomassie-stained SPS-PAGE gels were analyzed by densitometry using ImageJ 1.47 (W. Rasband, National Institutes of Health).
Data were further analyzed using paired or unpaired t-tests in Graph Pad Prism 5 (GraphPad Software, La Jolla, CA) or by ANOVA with Bonferroni post hoc test when necessary. All data are given as means Ϯ SE. P Ͻ 0.05 was considered significant.
RESULTS
Acute Effects of Angiotensin II on the Albumin GSC
To assess the acute effects of angiotensin II on the GSC of albumin, angiotensin II was infused at a constant rate of 10 ng·kg Ϫ1 ·min Ϫ1 . During the systemic infusion of angiotensin II, the MAP increased from 99.5 Ϯ 5.3 mmHg (the baseline value) to a maximum value of 171.9 Ϯ 7.3 mmHg and then decreased until the value stabilized at 137.5 Ϯ 5.7 mmHg (P Ͻ 0.0001 vs. baseline) ϳ10 min after the initial MAP increase. The albumin GSC was measured during this stable phase. The baseline albumin GSC in MWF rats was low, with an average value of 0.00044 Ϯ 4.8 ϫ 10 Ϫ5 (n ϭ 26). During the systemic infusion of angiotensin II, the albumin GSC increased by 286% to a value of 0.0017 Ϯ 0.00022 (P Ͻ 0.0001; n ϭ 22). Single data points are shown in Fig. 2A , indicating substantial differences in the changes in the albumin GSC among single glomeruli during angiotensin II infusion. To exclude the time-and volume-dependent changes in the albumin GSC, saline was infused in a control experiment at the same rate (0.09 l·g Ϫ1 ·min Ϫ1 ), and the albumin GSC measurements were taken within the same time interval used for the angiotensin II infusion experiment. In the control experiments, the MAP did not significantly change, with an average value of 105.5 Ϯ 8.8 mmHg before infusion and an average value of 99.9 Ϯ 7.3 mmHg 60 min after infusion (n ϭ 4). No difference in the albumin GSC was detected over time in the control experiments (n ϭ 15; Fig. 2B ).
The increase in the albumin GSC after the angiotensin II infusion was accompanied by a significant uptake of the labeled albumin by proximal tubular cells. Therefore, the proximal tubular albumin uptake, measured as an increase in the tubular fluorescence intensity during the time interval after the start of the Alexa-albumin infusion, was significantly higher during angiotensin II infusion than in the control condition (518 Ϯ 29% of the baseline value during angiotensin II infusion vs. 218 Ϯ 15% in the control; P Ͻ 0.0001; n ϭ 28; Fig. 3) . Additionally, the lumen of several late proximal tubules, which appeared black under the baseline condition, appeared to contain red Alexa albumin-dependent fluorescence after the angiotensin II infusion (Fig. 4) . Furthermore, there was intense fluorescence in the distal convoluted tubules where filtered dye molecules became concentrated after the angiotensin II infusion, which indicates that the proximal tubular uptake had reached saturation (Fig. 4C) . The presence of Alexa albumin in the distal convoluted tubule was also confirmed by a significant increase in the amount of albumin excreted in the urine during angiotensin II infusion. The albumin/osmolarity ratio in the urine increased ϳ20-fold, with an average value of 0.0013 Ϯ 0. 
Acute Effects of Angiotensin II on the snGFR
Because changes in the snGFR in response to angiotensin II infusion may influence the albumin GSC (8, 14, 19) , snGFR was determined before and after the infusion of angiotensin II. The snGFR averaged 17.8 Ϯ 1.9 nl/min at baseline and was reduced to 11.1 Ϯ 1.9 nl/min during infusion of angiotensin II (Ϫ38%; P ϭ 0.008; n ϭ 14; Fig. 5) .
Role of the Angiotensin II Receptor Subtypes AT 1 and AT 2 in the Angiotensin II-Induced Albumin GSC Increase
Because the albumin GSC increased significantly during the angiotensin II infusion, we next investigated which receptor type was involved. To investigate the role of the AT 1 receptor, losartan was administered 25 min after the start of the angiotensin II infusion. Inhibiting the AT 1 receptor decreased the MAP from 137.5 Ϯ 5.7 to 117.4 Ϯ 1.9 mmHg (P ϭ 0.0206, compared with the MAP during angiotensin II infusion; n ϭ 5). This decreased MAP value was still slightly higher than the baseline value (99.5 Ϯ 5.3 mmHg, n ϭ 7). When the losartan treatment was administered, the glomerular albumin filtration returned to the baseline level to an average GSC of 0.00037 Ϯ 5.8 ϫ 10 Ϫ5 (P Ͻ 0.001 vs. angiotensin II; n ϭ 16; Fig. 6A ).
To study the role of the AT 1 receptor in regulating the albumin filtration under the baseline condition (i.e., the endogenous angiotensin II concentration level), a control experiment using saline infusion was performed. The MAP decreased from 115 Ϯ 7.3 mmHg to 75 Ϯ 5 mmHg after the losartan treatment (n ϭ 4), while the albumin GSC did not change (n ϭ 15; Fig. 6A ).
To exclude any irreversible effects the angiotensin II infusion may have had on the filtration barrier before inhibiting the AT 1 receptor, a second experiment was performed in which losartan was injected before the start of the angiotensin II infusion. Inhibiting the AT 1 receptor in this context abolished any changes in the MAP that occurred during the infusion of angiotensin II, and the albumin GSC remained unchanged from the baseline value (n ϭ 10; Fig. 6B ).
To investigate the role of the AT 2 receptor in the angiotensin II-mediated changes in albumin filtration, we used the AT 2 receptor antagonist PD123319. This antagonist was injected before the start of the angiotensin II infusion. Inhibiting the AT 2 receptor did not alter the angiotensin II-induced changes in the MAP, which increased from 106.4 Ϯ 3.3 mmHg to a peak value of 166.4 Ϯ 4.6 mmHg and then stabilized at 135.9 Ϯ 6.2 mmHg ϳ10 min later (n ϭ 5). In the presence of PD123319, the albumin GSC increased from 0.0005 Ϯ 3.3 ϫ 10 Ϫ5 (n ϭ 24) to 0.0018 Ϯ 0.00035 (n ϭ 23; P ϭ 0.0004 vs. baseline) after angiotensin II infusion; these findings are similar to the results obtained when PD123319 is absent (Fig. 7A) . To reveal any possible AT 1 receptor-independent effects of angiotensin II on the albumin GSC, losartan was injected after inhibiting AT 2 receptors. The PD123319 treatment significantly elevated the albumin GSC during the angiotensin II infusion in the presence of the AT 1 inhibitor, with an average value of 0.00115 Ϯ 0.00015 (n ϭ 22) in the presence of the antagonist and an average value of 0.00037 Ϯ 5.8 ϫ 10
Ϫ5
(n ϭ 16) when PD123319 is absent (Fig. 7A) .
In a control experiment, PD123319 was injected before the infusion of saline to evaluate the role of the AT 2 receptor in albumin filtration at the endogenous angiotensin II concentration level. The PD123319 treatment increased the albumin GSC from 0.00052 Ϯ 3.6 ϫ 10 Ϫ5 (n ϭ 19) to 0.00074 Ϯ 8.2 ϫ 10 Ϫ5 (n ϭ 21; P ϭ 0.021), without any concomitant changes in the MAP (Fig. 7B) .
Taken together, these results show that the AT 1 and AT 2 receptors regulate opposing effects on the albumin GSC. The AT 1 receptor predominantly increases and the AT 2 receptor decreases the albumin GSC.
Role of the Renal Perfusion Pressure in Angiotensin II-Induced Changes in the Albumin GSC
To investigate the role of the MAP on the albumin GSC during angiotensin II infusion, a correlative analysis of the MAP vs. the GSC was performed. When the albumin GSC was plotted against the MAP, a weak, but significant, correlation between the two variables was observed (r 2 ϭ 0.264, df ϭ 46; P Ͻ 0.001).
Because this correlation between the MAP and albumin GSC appears to be weak and is presumably not entirely responsible for the changes in the albumin GSC during angiotensin II infusion, we next investigated the effects of angiotensin II on the albumin GSC when the renal perfusion pressure is kept constant. To investigate these effects, the albumin GSC was measured during the angiotensin II infusion in two different experiments in which the renal perfusion pressure was under mechanical control. In the first experiment, a string loop was implanted around the abdominal aorta (upstream of where the renal arteries branch) and the angiotensin II was infused without manipulating the renal perfusion pressure. The arterial pressure was measured in the femoral artery and increased from 102.3 Ϯ 2.3 (n ϭ 3) to a stable level of 135.7 Ϯ 2.1 mmHg during the angiotensin II infusion (n ϭ 3). This increase in pressure was accompanied by an increase in the albumin GSC from 0.00051 Ϯ 7.3 ϫ 10 Ϫ5 to 0.0022 Ϯ 0.00062 (P Ͻ 0.01; n ϭ 7). The pressure-independent effects of angiotensin II on the albumin GSC were then evaluated after normalizing the renal perfusion pressure by tightening the string loop. The arterial pressure in the femoral artery (and presumably in the renal artery) was reduced from 135.7 Ϯ 2.1 to 107.5 Ϯ 2.7 mmHg (n ϭ 3) to a level close to the baseline value. Despite the significant reduction in the renal perfusion pressure, the albumin GSC remained high, with an average value of 0.0023 Ϯ 0.00044 (n ϭ 7); this value is similar to the value calculated before the stenotic reduction in renal perfusion pressure (P ϭ 0.87; Fig. 8A) .
To evaluate the possible permanent effects of the temporarily elevated renal perfusion pressure on the albumin GSC after angiotensin II infusion, a second experiment was performed in which the renal perfusion pressure was kept constant at the baseline level by tightening the string loop around the descending aorta during the angiotensin II infusion. No significant change in the poststenotic arterial pressure was detected, but the albumin GSC did increase from 0.0007 Ϯ 0.00019 (n ϭ 9) before to 0.0025 Ϯ 0.00063 (n ϭ 9) after angiotensin II infusion (P ϭ 0.048; Fig. 8B ).
In summary, angiotensin II acutely alters the albumin GSC, and this effect appears to be largely independent of changes in the renal perfusion pressure.
DISCUSSION
The antiproteinuric effects of the inhibition of the RAS are well known, but the underlying mechanisms responsible for these effects have not yet been fully elucidated. In the present study, we investigated the acute effects of angiotensin II on the albumin GSC using in vivo multiphoton microscopy. We found that 1) the albumin GSC under baseline conditions is low in rats, 2) angiotensin II treatment results in an acute and significant increase in the albumin GSC, 3) the effect of angiotensin II on the albumin GSC is largely independent of the renal perfusion pressure, and 4) this effect is predominantly mediated by the AT 1 receptor and is partially mitigated by the AT 2 receptor. The intensity measurements of labeled albumin in the glomerular capillaries and Bowman's space revealed that young female MWF rats have a low baseline GSC for albumin, which indicates that an intact glomerulus is an effective barrier for the filtration of large-sized proteins. The overall average GSCs calculated for albumin in our experiments were ϳ0.0005. These values are similar to the values determined using invasive micropuncture techniques. With the use of micropuncture techniques, the GSC of albumin in the rat has been shown to be in the range of 0.0003 to 0.0006 (24, 40, 43) . These findings are consistent with a recent study using multiphoton microscopy that reported a GSC of albumin Ͻ0.002 in 40-day-old male MWF rats (21, 26) and of 0.002 in MW Simonsen rats of both sexes (41) . These levels are slightly higher than the values calculated in our study, but this difference may be related to gender differences, which appear to be especially relevant in the MWF rat strain. Female MWF rats are significantly less affected by the spontaneous development of glomerulosclerosis while aging (9, 28, 35) . Consistent with these findings, the amount of urinary protein excreted by the young female MWF rats used in our study was similar to that of age-matched Wistar rats, which suggests that the filtration barrier is completely functional at a young age (data not shown).
It should be mentioned that the use of multiphoton microscopy to assess the characteristics of the filtration barrier for Albumin GSC Fig. 6 . Effect of the AT1 receptor antagonist losartan (9.9 g/g body wt) injected after (A) and before (B) the infusion of angiotensin II. Control animals received a constant infusion of saline at the same rate used for the angiotensin II infusion (0.09 l·g Ϫ1 ·min
Ϫ1
).
macromolecules has been somewhat controversial. For example, Russo and colleagues (31, 32) , using multiphoton microscopy, recently reported nephrotic levels for the baseline GSC of albumin that were ϳ50 times higher than those found using micropuncture and significantly higher than those observed in the present study. The authors suggested that this large amount of filtered albumin would be compensated for by a massive protein uptake in the proximal tubule (32) . To reconcile these contrasting results, it was proposed that the condition of the animal (volume status, blood pressure, and body temperature) may account for some of these observed differences (41) . Our data suggest that conditions such as hypovolemia, low renal perfusion pressure, and low body temperature, all of which lead to an activation of the RAS (6), may substantially increase the GSC of albumin by angiotensin II-dependent mechanisms. These parameters appear to be particularly important when acquiring a baseline value for the GSC of albumin and other macromolecules. Furthermore, regarding possible technical issues, the out-offocus fluorescence in the capillaries immediately above or below the focus plane may cause inaccurately high fluorescence readings in the Bowman's space, especially when using external detectors (15, 26, 41, 42) . Therefore, we collected z-stacks of the glomerulus using low laser power before measuring the intensity in the Bowman's space to avoid regions of interest that were in close proximity to capillary loops.
A key finding of this study was that angiotensin II induces a rapid increase in the albumin GSC and that this effect is mediated by the AT 1 receptor. Because we used a protocol for acute angiotensin II infusion, it appears unlikely that the increase in the albumin GSC is related to any chronic structural changes to the glomerulus, such as glomerulosclerosis. These data are consistent with a recent study that showed that there was an increase in the filtration and urinary excretion of Ficoll after the infusion of angiotensin II (3). The effects of angiotensin II on the GSC of albumin in our study were inhibited when the rats were treated with the AT 1 antagonist losartan before angiotensin II infusion and completely reversed when the rats were treated with losartan after the GSC had increased in response to the angiotensin II infusion. These results suggest that the activation of the AT 1 receptor primarily mediates the enhanced glomerular filtration of albumin. Based on this proposed mechanism, it was surprising that the AT 1 antagonist did not reduce the baseline GSC of albumin; however, this finding is most likely due to the technical limitations of determining GSC levels lower than the baseline level. In addition to modulating the albumin GSC, angiotensin II reduced the snGFR by ϳ38%. Assuming a constant filtration coefficient K f , the reduced snGFR during angiotensin II infusion would suggest that the net filtration pressure had decreased. Because blood pressure in the femoral artery and, by inference, in the renal artery increased during angiotensin II infusion, an increase in the resistance ratio of the afferent/efferent arterioles most likely caused a reduction in the snGFR (2) .
The inhibitory effect of angiotensin II on the snGFR may in part be responsible for the observed GSC changes during angiotensin II infusion, since the contribution of diffusion to the movement of albumin across the filtration barrier increases considerably when GFR declines markedly (19) . Assuming that the baseline snGFR in our study was in the normal range for a rat, and that snGFR was moderately reduced during angiotensin II infusion, we believe that the increase in the albumin GSC during angiotensin II infusion likely is mediated by GFR-dependent and by GFR-independent mechanisms. In the isolated perfused rat kidney, the albumin GSC was shown to increase with GFR, an effect that was presumably related to increased glomerular capillary pressure and that was restricted to molecules of large molecular weight (23) . According to the two-pore model of filtration (7, 29) , this could be caused by an increase in the number of large pores when glomerular capillary pressure increases (16) . In this case, a reduction in the snGFR and, by inference, a reduced glomerular capillary pressure, would counteract the rise in the albumin GSC during angiotensin II infusion.
The level of glomerular albumin leakage increased up to fivefold in the presence of angiotensin II. It should be mentioned that angiotensin II reduced the glomerular blood flow velocity in some glomeruli; this reduction can result in a relative overestimation of the capillary fluorescence intensity, which would result in a lower GSC calculation; as a result, the true increase in the GSC of albumin caused by angiotensin II in some glomeruli may be even greater.
In addition to activating the AT 1 receptor, angiotensin II appears to also regulate the GSC of albumin through the AT 2 receptor. The effects of AT 1 receptor activation on the GSC were partially attenuated by the AT 2 receptor. The AT 2 antagonist increased the albumin GSC under the baseline conditions (i.e., the endogenous angiotensin II level), which suggests that the baseline GSC of albumin is determined by opposing AT 1 -and AT 2 -dependent mechanisms. During angiotensin II infusion with concomitant AT 1 inhibition, the AT 2 antagonist increased the GSC of albumin, which indicates that the AT 2 -dependent changes in the GSC are normally masked by the dominating effects of AT 1 receptor activation. When angiotensin II was infused without inhibiting AT 1 , the GSC of albumin did appear to increase during AT 2 blockade, but this did not reach a significant level. We believe that the GSC levels observed under this condition may represent the highest possible increase in the permeability of the filtration barrier that is acutely inducible by angiotensin II.
Taken together, these findings suggest that the specific activation of the AT 2 receptor has a protective role in regulating the filtration of albumin. This idea is further supported by the findings in models of chronic kidney injury. Proteinuria in a renal ablation model was higher in AT 2 receptor-deficient mice than in wild-type mice (4) . This difference in proteinuria between the genotypes was not related to the blood pressure or the expression level of the AT 1 receptor (4). These findings contribute to the ongoing controversy on whether ACEi or angiotensin receptor blockers are more beneficial in treating chronic kidney disease (30) . Although the results from human studies remain controversial, our data suggest that maintaining AT 2 receptor activation during RAS inhibition may reduce the filtration of proteins, which would cause the effect of the AT 1 antagonists to be more beneficial than that of ACEi.
Both the AT 1 and AT 2 receptors are expressed in podocytes, and it has been estimated that the AT 1 and AT 2 receptors account for 75 and 25% of podocyte angiotensin II binding, respectively (36, 38, 44) . Angiotensin II interactions with the AT 1 and AT 2 receptors have been shown to regulate the intracellular calcium levels, cAMP concentration, and membrane potential of cultured podocytes (10 -12) . Additionally, angiotensin II also influenced the cytoskeletal function and therefore the structure of the foot processes. Although the functional consequences of these contractions remain unclear, it is reasonable to assume that podocyte contractions may increase the leakiness of the filtration barrier for macromolecules such as albumin (17, 18) . Additionally, podocyte contractions reduce the dimensions of the subpodocyte space, the area between the basement membrane and the podocytes, which restricts the movement of the molecules across the glomerular capillary wall (22, 33) . Similar to what is observed in podocytes, cultured mesangial cells constrict when they are exposed to angiotensin II, an effect that is mediated by the AT 1 receptor (39) . If a similar contraction occurs in vivo, angiotensin II may reduce the surface area of the filtration barrier and this would cause a reduction in the snGFR for a given net filtration pressure, which in turn may influence the albumin GSC (19) . AT 1 and AT 2 receptor are also found in the glomerular endothelial cells, but their role in the control of glomerular hemodynamics and the permselectivity of the filtration barrier remains to be determined (45) .
The beneficial effects of RAS inhibition in alleviating proteinuria are the result of blood pressure-dependent and -independent changes. In the acute settings of our experiments, angiotensin II caused an increase in the GSC of albumin that was largely independent of the changes in renal perfusion pressure. Thus, when the renal perfusion pressure was kept constant by a mechanically variable stenosis upstream of the renal artery, the changes in the GSC of albumin in response to angiotensin II were preserved. It should be noted, however, that the autoregulatory capacity of the kidney under normal conditions markedly alleviates perturbations of renal perfusion caused by changes in the systemic arterial blood pressure, even during angiotensin II infusion (20) .
Consistent with our findings, in vitro experiments in the isolated perfused kidney have shown that there is an angiotensin II-induced and dose-dependent increase in the albumin filtration, even when the renal perfusion pressure is kept constant (18) . With the use of a more indirect in vivo approach, it was shown that angiotensin II enhances the filtration of Ficoll molecules Ͼ34 Å in radius, even in the presence of the calcium channel blocker nimodipine, which suppresses hemodynamic changes (3) . In contrast to these and our results, Bohrer et al. (5) suggested that the proteinuric effect of angiotensin II is largely due to its hemodynamic action. This discrepancy may be related the dose of angiotensin II and the details of the experimental settings and may indicate that there are multiple factor impinging on the modulation of the albumin GSC.
Although changes in the renal perfusion pressure are most likely not the primary cause of proteinuria during an acute increase in angiotensin II, it appears that an elevated arterial pressure after chronic angiotensin II exposure results in glomerular capillary lesions that eventually increase the leakiness of the filtration barrier for macromolecules (27) .
In summary, the in vivo evaluation of the filtration of albumin by multiphoton microscopy in anesthetized rats revealed that the glomerular filtration of albumin under baseline conditions is minimal. Angiotensin II, however, causes a rapid and pressure-independent increase in the GSC of albumin that is mediated by the AT 1 receptor and partially attenuated by concomitant AT 2 receptor activation.
